Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 15/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 10/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276251 | 0.93 | TP53 (0.59) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL2489859 | 0.93 | TP53 (0.59) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL276560 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL8354220 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL277153 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL11876775 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL5882600 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL28997915 | 0.91 | TP53 (0.57) | TP53CA2OPRM1CA1CA9 | |
| SCHEMBL222996 | 0.84 | — | — | |
| SCHEMBL22811253 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561255-A | 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors | 辉瑞公司 | 2024-02-13 | — | — | CN | claimed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | claimed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| CN-117561255-A | 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors | 辉瑞公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| CN-110143999-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚省公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4071239-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-114901810-A | Method for culturing hematopoietic stem cells | 住友制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| WO-1999043285-A2 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-4136164-A | FOR USE IN FOODS, TOPICAL PREPARATIONS, AND TOBACCO | WILKINSON SWORD LIMITED (GB) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TP53 55/4885CA2 3603/4885OPRM1 4147/4885 |
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | HCLS1, KIT, MCL1 | TP53 2593/4885CA2 1709/4885OPRM1 4407/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TP53 55/4885CA2 3603/4885OPRM1 4147/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | TP53 55/4885CA2 3603/4885OPRM1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.